Consolidated Portfolio Review Corp Vertex Pharmaceuticals Inc Transaction History
Consolidated Portfolio Review Corp
- $796 Billion
- Q3 2025
A detailed history of Consolidated Portfolio Review Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Consolidated Portfolio Review Corp holds 1,002 shares of VRTX stock, worth $434,888. This represents 0.05% of its overall portfolio holdings.
Number of Shares
1,002Holding current value
$434,888% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding VRTX
# of Institutions
1,791Shares Held
231MCall Options Held
1.84MPut Options Held
1.21M-
Capital World Investors Los Angeles, CA25.9MShares$11.2 Billion1.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.2MShares$10.5 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.25 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA16.6MShares$7.18 Billion1.27% of portfolio
-
State Street Corp Boston, MA11.6MShares$5.04 Billion0.16% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $111B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...